The Wyss Institute’s Brain Targeting Program (BTP), led by Principal Investigator James Gorman, M.D., Ph.D. and Co-PI Donald Ingber, M.D., Ph.D., is developing brain delivery technologies that enable development of breakthrough brain-targeted therapeutics for diverse brain diseases. Our brain delivery platform enables these therapeutic advances by dramatically improving transport of drugs across the blood-brain barrier (BBB) into the brain. We are looking for a talented scientist to contribute to the development and characterization of our novel antibody brain shuttle compounds and to optimize our shuttles for specific payloads in neurodegenerative diseases. [001369SR]